Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT(R) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT(R) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) GlobeNewswire January 05, 2026 – Initial module submission marks an important milestone in the pre-market approval process – – Flexible modular submission framework granted to Alpha Tau by the FDA allows for […]